ClouDr Group Ltd

ClouDr Group Ltd has a market price of 0.75 and a market cap of 484.29 million, with a price-to-book ratio of 0.88 and a price-to-tangible-book ratio of 0.88, indicating a discount to book value. The company's liquidity position is characterized by a current ratio of 1.03 and cash and equivalents of 267.64 million, but its net cash is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity of -1.68 and a return on assets of -0.55, both significantly below the industry median for Medical Equipment, Supplies & Distribution, which typically shows positive returns. The company's operating income is negative at -934.21 million, and its net income is also negative at -924.15 million, indicating a challenging operating environment. The company's revenue is concentrated in two main segments: in-hospital solutions and out-of-hospital solutions. In-hospital solutions include the sale of hospital supplies and SaaS, while out-of-hospital solutions include pharmacy supplies, SaaS, and chronic condition product sales. The geographic exposure is not disclosed in detail, but the company operates in both domestic and overseas markets. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. However, the negative operating and net income suggest a lack of growth in the near term. Historical revenue data shows a total of 1.62 billion, but without prior-year comparisons, it is difficult to assess growth trends. Risk factors include a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.53, and its long-term debt is 288.63 million, which is manageable but could become a concern if earnings do not improve. The risk assessment also notes that net cash is negative after subtracting total debt, which could lead to liquidity constraints. Recent events include the 2023 annual report, which outlines the company's operations and financial performance. No significant new filings or transcripts have been disclosed that would indicate a material change in the company's strategic direction or financial health.